Pharmaron (03759) has announced that all conditions have been met and the placement was successfully completed on January 22, 2026. The placing agent, acting in accordance with the terms and conditions of the placing agreement, successfully placed a total of 58.44 million placing shares to no fewer than six independent placees at a placing price of HK$22.82 per share. The net proceeds from the placement amount to HK$1.319 billion and are intended to be used as follows: approximately 70% will be allocated to the company's project construction to enhance the capabilities and capacity of its laboratory service facilities and drug process development and manufacturing facilities; approximately 10% will be used to repay bank loans and other borrowings to optimize the company's capital structure; and the remaining 20% will be utilized to supplement working capital and for other general corporate purposes.